Tetracycline therapy: Update
Tetracycline therapy: Update
复制标题
DOI：
10.1086/367622
复制
发表时间：
2003-02-15
影响因子：
11.8
通讯作者：
Roberts, MC
中科院分区：
文献类型：
--
作者：
Roberts, MC
自20世纪50年代以来，四环素类药物已用于治疗各种革兰氏阳性和革兰氏阴性细菌感染。除了对传统细菌有效外，四环素类还用于治疗细胞内衣原体、支原体、立克次体和原生动物寄生虫引起的感染以及各种非感染性疾病。它们对于治疗和预防可能用于生物武器的细菌感染非常重要。在引入治疗后不久，确定了细菌对四环素的耐药性。目前，细菌中四环素耐药可通过获得大于或等于36个不同基因中的1个，通过宿主外排泵或其16S rRNA序列的突变，或通过细胞通透性的改变而发生。相比之下，四环素抗性尚未在原生动物或其他真核生物中描述。
Tetracyclines have been used for treatment of a wide variety of gram-positive and gram-negative bacterial infections since the 1950s. In addition to being effective against traditional bacteria, tetracyclines have been used to treat infections due to intracellular chlamydiae, mycoplasmas, rickettsiae, and protozoan parasites and a variety of noninfectious conditions. They are important for treatment of and prophylaxis against infections with bacteria that could be used in biological weapons. Bacterial resistance to tetracycline was identified shortly after the introduction of therapy. At present, tetracycline resistance in bacteria can occur by acquisition of greater than or equal to1 of the 36 different genes, by mutations to host efflux pumps or in their 16S rRNA sequences, or by alteration in the permeability of the cell. In contrast, tetracycline resistance has not yet been described in protozoa or other eukaryotic organisms.